Sofamor Danek asking FDA to clarify "Dear Doctor" letter promotions policy.
This article was originally published in The Gray Sheet
Executive Summary
SOFAMOR DANEK TO SEEK CLARIFICATION OF FDA POLICY ON "DEAR DOCTOR" LETTERS in upcoming correspondence to the agency. Responding to an Aug. 22 letter from FDA regarding promotion of the TSRH Pedicle Spinal Implant System, the company wants the agency to clarify what information on device warnings must be included in Dear Doctor letters.
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.